SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ertugliflozin / Metformin Formulation

Version 3.6
Revision Date: 09.04.2021
SDS Number: 595333-00013
Date of last issue: 10.10.2020
Date of first issue: 01.04.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name: Ertugliflozin / Metformin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company: MSD
   Kilsheelan
   Clonmel Tipperary, IE
   Telephone: 353-51-601000
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4
   H302: Harmful if swallowed.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms:
   !
   Signal word: Warning
   Hazard statements: H302 Harmful if swallowed.
   Precautionary statements: Prevention:
   P264 Wash skin thoroughly after handling.
   P270 Do not eat, drink or smoke when using this product.
   Response:
   P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
Hazardous components which must be listed on the label:
metformin hydrochloride

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin hydrochloride</td>
<td>1115-70-4</td>
<td>214-230-6</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302</td>
<td>&gt;= 70 - &lt; 90</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302; Skin Corr. 1B; H314; Eye Dam. 1; H318; STOT RE 2; H373 (Kidney, Stomach, Prostate)</td>
<td>&gt;= 0,1 - &lt; 1</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled : If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed
Risks : Harmful if swallowed.

Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

5.3 Advice for firefighters
Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
for firefighters

Specific extinguishing methods:
- Use personal protective equipment.
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
Ertugliflozin / Metformin Formulation

Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control: Exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin hydrochloride</td>
<td>1115-70-4</td>
<td>TWA</td>
<td>1 mg/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

**Personal protective equipment**

**Eye protection**
Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**
Chemical-resistant gloves

**Remarks**
Consider double gloving.

**Skin and body protection**
Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143

**Filter type**
Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Lower explosion limit / Lower flammability limit: No data available
Flash point: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
pH: No data available
Viscosity: Not applicable
Solubility(ies):
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Vapour pressure: Not applicable
Relative density: No data available
Density: No data available
Relative vapour density: Not applicable
Particle characteristics:
Particle size: No data available

9.2 Other information:
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1.337 mg/kg
Method: Calculation method

Components:

metformin hydrochloride:
Acute oral toxicity: LD50 (Rat): 1.000 mg/kg
LD50 (Mouse): 1.450 - 3.500 mg/kg
LD50 (Monkey): 463 mg/kg
LD50 (Rabbit): 350 mg/kg
LD50 (Guinea pig): 500 mg/kg

Ertugliflozin:
Acute oral toxicity: LD50 (Rat): 500 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Not classified based on available information.

Components:

metformin hydrochloride:
Species: Rabbit
Ertugliflozin / Metformin Formulation

Result : Mild skin irritation

**Ertugliflozin:**
Result : Corrosive

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**
**metformin hydrochloride:**
Species : Rabbit
Result : Mild eye irritation

**Ertugliflozin:**
Result : Severe irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**
**Ertugliflozin:**
Test Type : Local lymph node assay (LLNA)
Result : Not a skin sensitizer.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**
**metformin hydrochloride:**
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative
Ertugliflozin / Metformin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

**Ertugliflozin:**

Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: negative

Genotoxicity in vivo
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Rat
  Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:**

**Metformin hydrochloride:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>91 weeks</td>
</tr>
<tr>
<td>Dose</td>
<td>1500 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>104 weeks</td>
</tr>
<tr>
<td>Dose</td>
<td>900 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>104 weeks</td>
</tr>
<tr>
<td>LOAEL</td>
<td>900 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Uterus (including cervix)</td>
</tr>
<tr>
<td>Remarks</td>
<td>The mechanism or mode of action may not be relevant in humans.</td>
</tr>
</tbody>
</table>

**Ertugliflozin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Carcinogenicity - Assessment**

Weight of evidence does not support classification as a carcinogen.
Reproductive toxicity
Not classified based on available information.

**Components:**

**metformin hydrochloride:**

Effects on fertility:
- Test Type: Fertility
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 600 mg/kg body weight
  - Result: No effects on fertility

Effects on foetal development:
- Test Type: Development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 600 mg/kg body weight
  - Result: No teratogenic effects

**Ertugliflozin:**

Effects on fertility:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 250 mg/kg body weight
  - Remarks: Maternal toxicity observed.
  - No significant adverse effects were reported

- Test Type: Fertility/early embryonic development
  - Species: Rabbit
  - Application Route: Oral
  - Fertility: NOAEL: 200 mg/kg body weight
  - Remarks: No significant adverse effects were reported

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 50 mg/kg body weight
  - Remarks: Adverse developmental effects were observed

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 250 mg/kg body weight
  - Remarks: No significant adverse effects were reported
Ertugliflozin / Metformin Formulation

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Ertugliflozin:
Exposure routes : Oral
Target Organs : Kidney, Stomach, Prostate
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

metformin hydrochloride:
Species : Rat
NOAEL : 125 mg/kg
Application Route : Oral
Exposure time : 1 year
Remarks : No significant adverse effects were reported

Species : Rabbit
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 1 Year
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 2 year
Remarks : No significant adverse effects were reported

Ertugliflozin:
Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d
Target Organs : Kidney, Bone, Stomach
Species : Rat
LOAEL : 25 mg/kg
Exposure time : 90 d
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone
Remarks : No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

metformin hydrochloride:
Skin contact : Remarks: May irritate skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

Ertugliflozin:
Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection
SECTION 12: Ecological information

12.1 Toxicity

**Components:**

**metformin hydrochloride:**

- **Toxicity to algae/aquatic plants:**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

**Toxicity to microorganisms:**

- EC50 : > 1.000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Toxicity to fish (Chronic toxicity):**

- NOEC: 10 mg/l
  - Exposure time: 33 d
  - Species: Pimephales promelas (fathead minnow)
  - Method: OECD Test Guideline 210

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**

- NOEC: 40 mg/l
  - Exposure time: 21 d
  - Species: Daphnia magna (Water flea)
  - Method: OECD Test Guideline 211

**Ertugliflozin:**

- **Toxicity to algae/aquatic plants:**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 50 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **Toxicity to microorganisms:**
  - EC50 : > 1.000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

- **NOEC :** 1.000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Toxicity to fish (Chronic toxicity):**

- NOEC: 1 mg/l
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- **Species:** Pimephales promelas (fathead minnow)
- **Method:** OECD Test Guideline 210
- **Remarks:** No toxicity at the limit of solubility

Exposure time: 32 d

NOEC: 2,14 mg/l

**12.2 Persistence and degradability**

**Components:**

**Metformin hydrochloride:**
- Biodegradability: Result: rapidly degradable
- Biodegradation: 50%
- Exposure time: 2 hrs

**Ertugliflozin:**
- Biodegradability: Result: Not readily biodegradable.
- Biodegradation: 40.8%
- Exposure time: 28 d

**12.3 Bioaccumulative potential**

**Components:**

**Metformin hydrochloride:**
- Partition coefficient: n-octanol/water: log Pow: -2

**Ertugliflozin:**
- Partition coefficient: n-octanol/water: log Pow: 2.47

**12.4 Mobility in soil**

**Components:**

**Metformin hydrochloride:**
- Distribution among environmental compartments: log Koc: 4.3
- Method: OECD Test Guideline 106

**Ertugliflozin:**
- Distribution among environmental compartments: log Koc: 2.88

**12.5 Results of PBT and vPvB assessment**

**Product:**
- Assessment: This substance/mixture contains no components considered
to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

**Product:** Endocrine disrupting potential

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**SECTION 13: Disposal considerations**

13.1 Waste treatment methods

**Product**

Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging**

Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information**

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks: Not applicable for product as supplied.

**SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable


The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H314 : Causes severe skin burns and eye damage.

H318 : Causes serious eye damage.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Eye Dam. : Serious eye damage

Skin Corr. : Skin corrosion

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Con-
Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
- Acute Tox. 4: H302

Classification procedure:
- Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN